Innovations In Clinical Neuroscience

MAR-APR 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: http://innovationscns.epubxp.com/i/822795

Contents of this Issue

Navigation

Page 25 of 45

Innovations in CLINICAL NEUROSCIENCE [ V O L U M E 1 4 , N U M B E R 3 – 4 , M A R C H – A P R I L 2 0 1 7 ] 26 TABLE 1. TCA and T3 trials STUDY AUTHORS DESIGN (N) TREATMENT RESULTS Coppen et al, 15 1972 Randomized, double- blind (15); Enhancement Imipramine 150mg/day + T3 25mcg/day or placebo x 4 weeks Women in T3 group vs. women taking placebo: 100% reduction in HRSD vs. 40% (ns) Men in T3 group vs. men taking placebo: 76% reduction in HRSD vs. 88% (ns) Feighner et al, 16 1972 Randomized, double- blind (21); Enhancement Imipramine 200mg/day + T3 25mcg/day or placebo x 22 days No significant difference in remission rates between groups Gitlin et al, 26 1987 Randomized, double- blind with crossover (16); Augmentation Imipramine up to 300mg/day x 4 weeks + T3 25mcg/day or placebo x 2 weeks; crossover x 2 weeks No significant difference response rates a between groups Joffe and Singer, 27 1990 Randomized, double- blind (38); Augmentation Desipramine or imipramine 2.5–3mg/kg x 4 weeks + T3 37.5mcg/day or T4 150mcg/day x 3 weeks T3 vs. T4: 53% response rate a vs. 19% (p=0.026) Joffe et al, 28 1993 Randomized, double- blind (50); Augmentation Desipramine or imipramine >2.5mg/kg x 5 weeks + T3 37.5mcg/day or lithium 900–1200mg/day or placebo x 2 weeks No significant difference in response rates a between T3 and lithium T3 vs. placebo: 59% response rate a vs. 19% (p=0.018) Prange et al, 17 1969 Randomized double-blind (20); Enhancement Imipramine 150mg/day + T3 25mcg/day or placebo x 4 weeks (T3 added on Day 5) T3 group achieved response a after 11 days vs. 22 days in placebo group Thase et al, 29 1989 Naturalistic, sequential with historical controls; open-label (40); Augmentation Imipramine + psychotherapy (MTRD protocol b ) alone x 12 weeks minimum vs. imipramine + psychotherapy x 12 weeks minimum + T3 25mcg/day x 4 weeks No significant difference in response rates c between groups Wheatley, 18 1972 Randomized, double- blind (52); Enhancement Amitriptyline 100mg/day + T3 20mcg/day or T3 40mcg/day or placebo x 3 weeks T3 20mcg/day vs. placebo after 14 days: 57% reduction in HRSD vs. 46% (p<0.01) T3 40mcg/day vs. placebo after 14 days: 74% reduction in HRSD vs. 46% (p<0.01) Wilson et al, 19 1970 Randomized, double- blind (20); Enhancement Imipramine 150mg/day + T3 25mcg/day or placebo x 4 weeks (T3 added on Day 5) T3 subjects significantly more improved than those taking placebo by Day 7 (p<0.01) Wilson et al, 20 1974 Randomized, double- blind (27); Enhancement Impramine 150mg/day + placebo or T3 25–62.5mcg/day + placebo or imipramine 150mg/day + T3 25–62.5mcg/day x 4 weeks (T3 added on Day 3, increased to 62.5mcg/day by Day 7 and stopped on Day 12) Imipramine + T3 subjects significantly more improved based on HRSD scores than those taking imipramine alone on Days 7 and 9 (p<0.05), but not on Days 5 and 12 No advantage of T3 alone vs. imipramine alone Some T3 toxicity noted after a few days of 62.5mcg/day TCA: tricyclic antidepressant; T3: liothyronine/triiodothyronine; T4: thyroxine; ns: not significant a : ≥50% decrease in HRSD b : Maintenance Therapies of Recurrent Depression (longitudinal investigation comparing the prophylactic efficacy of imipramine and interper- sonal psychotherapy) c : ≥50% decrease in HRSD and HRSD score of <10

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - MAR-APR 2017